Smartlab Europe

Clinical Trials

Dr Reddy’s Laboratories gets approval for phase 3 trials of Sputnik V Covid vaccine

Dr Reddy’s Laboratories (DRL) on Monday announced the start of its phase 3 clinical trial of Russia's Sputnik V Covid-19 vaccine after receiving clearance from the independent Data and Safety Monitoring Board (DSMB). DSMB’s clearance is based on the safety...

ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial

ICON plc,a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public health organisations, announced it provided clinical trial services to the Pfizer and BioNTech SE...

Phesi and Sensyne Health Agree Collaboration to Advance Development of Synthetic Arms in Clinical Trials

Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, announced it has entered into an exclusive strategic collaboration with clinical AI technology company, Sensyne Health, which is making an equity investment of $10 million in...

Bharat Biotech vaccine approved in clinical trial mode, consent of participants has to be taken: ICMR

Balram Bhargava, chief of Indian Council of Medical Research (ICMR), said on Tuesday that Bharat Biotech’s Covid-19 vaccine has been cleared in the clinical trial mode, which means consent of participants has to be taken. He was responding to...

Tiziana Life Sciences completes clinical trial of nasally administered Foralumab to treat COVID-19 in Brazil

Tiziana Life Sciences announced the completion of its clinical study in Brazil investigating nasally administered Foralumab, its proprietary human monoclonal antibody, either alone or in combination with orally administered dexamethasone in COVID-19 patients. The clinical study was completed in collaboration...

AbbVie, Boehringers Skyrizi yields positive results in Phase III psoriatic arthritis trials

AbbVie reported data from a pair of Phase III studies showing that Skyrizi (risankizumab) led to significantly more psoriatic arthritis patients achieving the primary endpoint of at least 20% improvement on American College of Rheumatology (ACR20) criteria than placebo...

Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

Vir Biotechnology, Inc. announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »